Á. Rovira

Serum Glial-Related Biomarkers Show Distinct Contributions to Radiologic and Clinical Outcomes in Early Multiple Sclerosis.

BACKGROUND AND OBJECTIVES To investigate the association between serum levels of glial-related biomarkers, including glycoprotein nonmetastatic melanoma B (GPNMB), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), galectin-3, serpin peptidase inhibitor clade A member 3 (SERPINA3), chitotriosidase-1 (CH...

Evaluation of the 2022 international consensus criteria for optic neuritis: the role of clinical features and visual evoked potentials

“Low‐Positive” MOG‐IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis

ABSTRACT Objective To determine the prevalence and clinical characteristics of patients with “low‐positive” (LP) MOG‐IgG (titres 1:160–1:320) among adults with a first demyelinating event (FDE) suggestive of multiple sclerosis (MS). Methods From the Barcelona CIS inception cohort, we included adult patients with serum...

MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review.

Importance Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion di...

Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease - MAGNIMS consensus recommendations.

A multidisciplinary multicentric approach to the identification of predictive biomarkers of response to erenumab – the protocol of the phase 4, European, open-label controlled trial of the BIOMIGA project

Background Migraine is a highly prevalent disease and the leading cause of years lived with disability in women. The development of therapies targeting the calcitonin gene-related peptide (CGRP) pathway has provided the first mechanism-based approach for migraine prevention. Although these treatments have demonstrated...

Application of the 2024 McDonald Criteria

This review contextualizes the implications of key revisions in the 2024 McDonald criteria for routine clinical care, while providing accessible guidance for its appropriate application with a lens toward nonspecialist clinicians and trainees globally, to ensure early and accurate MS diagnosis.

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.

Failure to reduce zNfL levels after 1 year of treatment was associated with subsequent disease activity, even in patients otherwise considered stable, providing complementary information to clinical and MRI-based monitoring.